| Title: | An integrative mendelian randomisation and drug mechanism framework for target prioritisation and therapeutic repurposing in major depression |
| Journal: | Translational Psychiatry |
| Published: | 2 Jun 2026 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/42230543/ |
| DOI: | https://doi.org/10.1038/s41398-026-04137-9 |
| URL: | https://www.nature.com/articles/s41398-026-04137-9_reference.pdf |
Publication 19798
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Major depression (MD) treatments have limited efficacy and target few mechanisms, highlighting the need for innovative drug discovery. Drugs targeting genetically supported proteins are 2.6 times more likely to succeed in drug development. Here, we use genetic methods to identify and prioritise MD drug targets, leveraging genome-wide association study (GWAS) summary statistics from >525,000 MD cases. We derived exposure data from 10 datasets measuring protein quantitative trait loci (pQTLs) and gene expression levels (eQTLs) in blood, cerebrospinal fluid, and brain tissues. We performed cis-Mendelian randomisation (MR) on 3469 druggable targets (genes encoding proteins targeted by existing compounds or experimentally predicted to be druggable). To strengthen causal inference, we implemented robust MR estimators, colocalisation, external replication, and assessed directional consistency across tissues. We integrated cis-MR effect directions with drug mechanisms and clinical annotations to infer potential therapeutic effects. Validation analyses showed that 82% of drugs approved for depression/anxiety had ≥1 significant MR target, compared to 51% for compounds in clinical trials. For repurposing, we prioritised 54 targets of compounds developed for other conditions with estimated beneficial effects on MD (e.g., an inhibitor for a risk-increasing target). Ten high-priority targets of brain-penetrating compounds included ACE and NISCH (cardiovascular drugs), NDUFA2, NDUFB6, and NDUFS1 (metformin), CDK4, NTRK3, and MET (oncology inhibitors), and GLS and NOS2 (enzyme inhibitors). We found genetic evidence for established and novel MD targets across the drug development pipeline. Novel targets point to mechanisms beyond monoaminergic systems, most with approved drugs for other conditions, offering immediate repurposing opportunities.</p>
10 Authors
- Abigail R. ter Kuile
- Chris Finan
- Sandesh Chopade
- Marion van Vugt
- Nikita Hukerikar
- Serena Barral
- Argyris Stringaris
- Amand F. Schmidt
- Karoline Kuchenbaecker
- Jean-Baptiste Pingault
1 Application
| Application ID | Title |
|---|---|
| 12113 | Harnessing associations of genetic and phenotypic traits for drug target validation, Ref: 12113. |
Enabling scientific discoveries that improve human health